CTOs on the Move

Accretech America Inc

www.accretechamerica.com

 
Accretech America Inc is a Fremont, CA-based company in the Computers and Electronics sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

eSilicon

Custom IC design isn`t simply about getting the highest performance anymore. It`s about hitting the target performance at the optimized power and area, on time, on budget, and getting into volume production for faster time to revenue. It`s about getting the right chip for your market. eSilicon, the largest independent semiconductor design and manufacturing services provider, delivers custom ICs and custom IP to OEMs, integrated device manufacturers (IDMs), fabless semiconductor companies (FSCs) and wafer foundries through a fast, flexible, lower-risk path to volume production. eSilicon serves a wide variety of markets including the communications, computer, consumer and industrial segments.

Nethra Imaging

Nethra Imaging, Inc. is a Santa Clara, CA-based company in the Computers and Electronics sector.

Strontium Americas Inc

Strontium Americas Inc is a Fremont, CA-based company in the Computers and Electronics sector.

Advanced Design Services

Advanced Design Services is a Melbourne, FL-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.